Results 191 to 200 of about 35,949 (266)

Novel approaches for drug development against chronic primary pain: A systematic review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus   +5 more
wiley   +1 more source

Reproductive health in the liver transplant recipient. [PDF]

open access: yesLiver Transpl
Dukewich M   +3 more
europepmc   +1 more source

Schedule‐dependent neuroprotection by pioglitazone in a novel model of α‐synucleinopathy in rats: Integrated behavioural and histological outcomes

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose α‐Synucleinopathies are neurodegenerative disorders characterized by the aggregation and propagation of misfolded α‐synuclein. In Parkinson's disease (PD), the most common α‐synucleinopathy, the progression of motor and nonmotor deficits, and dopaminergic neuron loss, are closely linked to the spreading of misfolded α‐synuclein ...
Alberto Santiago‐Balmaseda   +5 more
wiley   +1 more source

A qualitative study on healthcare providers' biases towards transgender and gender diverse people accessing contraceptive care. [PDF]

open access: yesSex Reprod Health Matters
Zia Y   +10 more
europepmc   +1 more source

Epidemiological Fact Sheets on HIV/AIDS and Sexually Transmitted Infections [PDF]

open access: yes, 2004
Joint United Nations Programme on HIV/AIDS, UNAIDS   +1 more
core  

A novel selective stabilizer of the ryanodine receptor 2 prevents stress‐induced ventricular arrhythmias without impairing cardiac function

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Aberrant activation of type 2 ryanodine receptors (RyR2) causes lethal arrhythmias, such as catecholaminergic polymorphic ventricular tachycardia (CPVT). Developing drugs that suppress RyR2 hyperactivation may be key to novel arrhythmia treatments.
Nagomi Kurebayashi   +29 more
wiley   +1 more source

A detailed review of pharmacokinetics/pharmacodynamics of progestogens in oral contraception. [PDF]

open access: yesFront Endocrinol (Lausanne)
Gaspard U   +3 more
europepmc   +1 more source

Diltiazem N‐oxide, a novel ischaemia‐activated prodrug, prevents ischaemia‐induced ventricular fibrillation without off‐target adverse effects

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Ventricular fibrillation (VF) in coronary heart disease accounts for up to 70% of sudden cardiac death. We examined whether diltiazem N‐oxide (DNO) has ischaemia‐selective antiarrhythmic activity. Experimental Approach Randomised and blinded experiments were performed in rat isolated hearts and in anaesthetised rats to ...
Louise M. Hesketh   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy